Cutera (CUTR) 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 30, 2020
Document Information [Line Items]
Entity Registrant Name	CUTERA INC
Entity Central Index Key	0001162461
Trading Symbol	cutr
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		17,463,025
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock ($0.001 par value)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,774	$ 26,316
Marketable investments	4,746	7,605
Accounts receivable, net of allowance for credit losses of $937 and $1,355, respectively	15,660	21,556
Inventories	36,941	33,921
Other current assets and prepaid expenses	4,831	5,648
Total current assets	76,952	95,046
Property and equipment, net	2,687	2,817
Deferred tax asset	408	423
Operating lease-right-of-use assets	7,143	7,702
Goodwill	1,339	1,339
Other long-term assets	5,901	6,411
Total assets	94,430	113,738
Current liabilities:
Accounts payable	14,604	12,685
Accrued liabilities	23,663	30,307
Operating lease liabilities	2,204	2,800
Extended warranty liability	1,765	1,999
Deferred revenue	10,180	10,831
Total current liabilities	52,416	58,622
Deferred revenue, net of current portion	2,789	3,391
Income tax liability	93	93
Operating lease liabilities, net of current portion	5,149	5,112
Other long-term liabilities	447	578
Total liabilities	60,894	67,796
Commitments and Contingencies (Notes 12 and 13)
Stockholders’ equity:
Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 14,578,146 and 14,315,586 shares at March 31, 2020 and December 31, 2019, respectively	15	14
Additional paid-in capital	82,292	82,346
Accumulated deficit	(48,772)	(36,358)
Accumulated other comprehensive income (loss)	1	(60)
Total stockholders’ equity	33,536	45,942
Total liabilities and stockholders’ equity	$ 94,430	$ 113,738

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Trade accounts receivable, allowance	$ 937,000	$ 1,354,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	50,000,000	50,000,000
Common stock, issued (in shares)	14,578,146	14,315,586
Common stock, outstanding (in shares)	14,578,146	14,315,586

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net revenue:
Revenue	$ 32,239,000	$ 36,026,000
Cost of revenue:
Cost of revenue	17,903,000	18,717,000
Gross profit	14,336,000	17,309,000
Operating expenses:
Sales and marketing	14,789,000	16,104,000
Research and development	3,870,000	3,706,000
General and administrative	7,806,000	5,525,000
Total operating expenses	26,465,000	25,335,000
Loss from operations	(12,129,000)	(8,026,000)
Interest and other expense, net	(207,000)	(79,000)
Loss before income taxes	(12,336,000)	(8,105,000)
Income tax expense	78,000	115,000
Net loss	$ (12,414,000)	$ (8,220,000)
Net loss per share:
Basic and Diluted (in dollars per share)	$ (0.86)	$ (0.59)
Weighted-average number of shares used in per share calculations:
Basic and Diluted (in shares)	14,433	14,017
Product [Member]
Net revenue:
Revenue	$ 26,391,000	$ 30,762,000
Cost of revenue:
Cost of revenue	14,103,000	15,541,000
Service [Member]
Net revenue:
Revenue	5,848,000	5,264,000
Cost of revenue:
Cost of revenue	$ 3,800,000	$ 3,176,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss	$ (12,414)	$ (8,220)
Available-for-sale investments
Net change in unrealized gain (loss) on available-for-sale investments		6
Less: Reclassification adjustment for losses on investments recognized during the period	61
Net change in unrealized gain (loss) on available-for-sale investments	61	6
Other comprehensive gain (loss), net of tax	61	6
Comprehensive loss	$ (12,353)	$ (8,214)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2018	13,968,852
Balance at Dec. 31, 2018	$ 14	$ 70,451	$ (24,010)	$ (69)	$ 46,386
Exercise of stock options (in shares)	15,032
Exercise of stock options		131			131
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes, and stock awards (in shares)	51,491
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes, and stock awards		(490)			(490)
Stock-based compensation expense		1,307			1,307
Net loss			(8,220)		(8,220)
Net change in unrealized gain on available-for-sale investments				6	6
Balance (in shares) at Mar. 31, 2019	14,035,375
Balance at Mar. 31, 2019	$ 14	71,399	(32,230)	(63)	$ 39,120
Balance (in shares) at Dec. 31, 2019	14,315,586				14,315,586
Balance at Dec. 31, 2019	$ 14	82,346	(36,358)	(60)	$ 45,942
Exercise of stock options (in shares)	22,291				22,291
Exercise of stock options		200			$ 200
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes, and stock awards (in shares)	240,269
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes, and stock awards	$ 1	(2,234)			(2,233)
Stock-based compensation expense		1,980			1,980
Net loss			(12,414)		(12,414)
Net change in unrealized gain on available-for-sale investments				61	$ 61
Balance (in shares) at Mar. 31, 2020	14,578,146				14,578,146
Balance at Mar. 31, 2020	$ 15	$ 82,292	$ (48,772)	$ 1	$ 33,536

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (12,414,000)	$ (8,220,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,980,000	1,307,000
Depreciation of tangible assets	360,000	411,000
Amortization of contract acquisition costs	717,000	690,000
Change in deferred tax asset	15,000	6,000
Provision for credit losses	590,000	98,000
Other	35,000	103,000
Changes in assets and liabilities:
Accounts receivable	5,306,000	403,000
Inventories	(3,020,000)	1,355,000
Other current assets and prepaid expenses	807,000	(916,000)
Other long-term assets	(207,000)	(679,000)
Accounts payable	1,919,000	(942,000)
Accrued liabilities	(6,567,000)	(1,467,000)
Extended warranty liabilities	(234,000)	(492,000)
Other long-term liabilities		(140,000)
Deferred revenue	(1,253,000)	525,000
Income tax liabilities		5,000
Net cash used in operating activities	(11,966,000)	(7,953,000)
Cash flows from investing activities:
Acquisition of property, equipment and software	(230,000)	(65,000)
Proceeds from maturities of marketable investments	6,800,000	3,200,000
Purchase of marketable investments	(3,930,000)	(1,586,000)
Net cash provided by investing activities	2,640,000	1,549,000
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan	201,000	131,000
Taxes paid related to net share settlement of equity awards	(2,234,000)	(490,000)
Payments on finance lease obligations	(183,000)	(131,000)
Net cash used in financing activities	(2,216,000)	(490,000)
Net decrease in cash and cash equivalents	(11,542,000)	(6,894,000)
Cash and cash equivalents at beginning of period	26,316,000	26,052,000
Cash and cash equivalents at end of period	14,774,000	19,158,000
Supplemental disclosure of non-cash items:
Assets acquired under capital lease		$ 192,000

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1. Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) provides energy-based aesthetic systems for practitioners worldwide. The Company designs, develops, manufactures, distributes and markets energy-based product platforms for use by physicians and other qualified practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: excel, enlighten, Juliet, Secret RF, truSculpt xeo truSculpt iD truSculpt flex Juliet Secret RF third Titan, truSculpt 3D, truSculpt flex The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company markets, sells and services the Company’s products through direct sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland and the United Kingdom. Sales and Services outside of these direct markets are made through a worldwide distributor network in over 40 Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not On January 30, 2020, 19 In March 2020, 19 19 19 19 third 19 120 180 Beginning in the second first 2020, 19, not In cases where its customers are working, they are performing fewer procedures. When they are performing procedures, customers are mostly focused on medically necessary procedures that should not may may second 2020, 2020, may In response to the COVID- 19 25% 25% 42% 2019 As a result of the events and impact surrounding the COVID- 19 no March 31, 2020. COVID–19 Unaudited Interim Financial Information In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements included in this report reflect all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of its consolidated statements of financial position as of March 31, 2020 2019, three March 31, 2020, 2019. December 31, 2019 not not 10 December 31, 2019 March 16, 2020. Accounting Policies These unaudited condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not 10 December 31, 2019 March 16, 2020. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the Notes to condensed consolidated financial statements refer to the Company’s continuing operations. Note 1 Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, and sales allowances, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, incremental borrowing rates related to the Company’s leases, assumptions regarding variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, fair value of investments, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Recently Adopted Accounting Pronouncements In June 2016, No. 2016 13, 326 2016 13 December 15, 2019, 2020, 2016 13 January 1, 2020 not The Company identified trade receivables and available-for-sale debt securities as impacted by the new guidance. However, the Company determined that the historical losses related to these available-for-sale debt securities are not The Company establishes an allowance for credit losses on trade receivables based on the credit quality of clients, current economic conditions, the age of the accounts receivable balances, historical loss information, and current conditions and forecasted information, and write-off amounts against the allowance when they are deemed uncollectible. At March 31, 2020 three March 31, 2020, 19 The Company’s allowance for credit losses was $937,000 $1,354,000 March 31, 2020 December 31, 2019. March 31, 2020, $590,000 $1,007,000 In August 2018, No. 2018 13, 820 3 1 2 3 2020, not Recently Issued Accounting Pronouncements Not In December 2019, No. 2019 12 740 2021, not

Note 2 - Cash, Cash Equivalents

Note 2 - Cash, Cash Equivalents and Marketable Investments	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Cash, Cash Equivalents, and Marketable Securities [Text Block]	Note 2. The Company invests its cash primarily in money market funds and in highly liquid debt instruments of U.S. federal and municipal governments and their agencies, commercial paper and corporate debt securities. All highly liquid investments with stated maturities of three three The Company determines the appropriate classification of its investments in marketable securities at the time of purchase and re-evaluates such designation at each balance sheet date. The Company’s marketable securities have been classified and accounted for as available-for-sale securities. Investments with remaining maturities of more than one 320. 326, not The following tables summarize the components, and the unrealized gains and losses position, related to the Company’s cash, cash equivalents and marketable investments (in thousands): March 31, 20 20 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Cash and cash equivalents $ 14,774 $ - $ - $ 14,774 Marketable investments: U.S. government notes 804 1 - 805 Commercial paper 3,941 1 (1 ) 3,941 Total marketable investments 4,745 2 (1 ) 4,746 Total cash, cash equivalents and marketable investments $ 19,519 $ 2 $ (1 ) $ 19,520 December 31, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Cash and cash equivalents $ 26,316 $ - $ - $ 26,316 Marketable investments U.S. government notes 4,114 - - 4,114 Commercial paper 3,491 - - 3,491 Total marketable securities 7,605 - - 7,605 Total cash, cash equivalents and marketable securities $ 33,921 $ - $ - $ 33,921 As of March 31, 2020 December 31, 2019, $1,000 Nil, not No 12 The following table summarizes the contractual maturities of the Company’s available-for-sale securities, classified as marketable investments as of March 31, 2020 ( Amount Due in less than one year $ 4,746 Due in 1 to 3 years - Total marketable investments $ 4,746

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three may 820, ● Level 1: ● Level 2: 1 not not third ● Level 3: no 3 In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. As of March 31, 2020, March 31, 20 20 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 9,224 $ - $ - $ 9,224 Marketable investments: Available-for-sale securities 805 3,941 - 4,746 Total assets at fair value $ 10,029 $ 3,941 $ - $ 13,970 As of December 31, 2019, December 31, 2019 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 6,311 $ - $ - $ 6,311 Short term marketable investments: Available-for-sale securities 4,114 3,491 - 7,605 Total assets at fair value $ 10,425 $ 3,491 $ - $ 13,916 Money market funds and U.S. Treasury bills are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 Corporate debt, U.S. government-backed securities, and commercial paper are measured at fair value using Level 2 not third 2 2 March 31, 2020 0.1 no March 31, 2020 December 31, 2019,

Note 4 - Balance Sheet Detail

Note 4 - Balance Sheet Detail	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 4. Inventories As of March 31, 2020 December 31, 2019, March 31, 20 20 December 31, 201 9 Raw materials $ 19,092 $ 17,935 Work in process 3,161 2,016 Finished goods 14,688 13,970 Total $ 36,941 $ 33,921 Accrued Liabilities As of March 31, 2020 December 31, 2019, March 31, 20 20 December 31, 201 9 Accrued payroll and related expenses $ 11,842 $ 14,341 Sales and marketing accruals 1,581 2,527 Warranty liability 3,398 4,401 Sales tax 1,443 3,922 Other 5,399 5,116 Total $ 23,663 $ 30,307 Product Remediation Liability During the fourth 2018, one one $5.0 2018. As of March 31, 2020 December 31 2019, $0.5 $1.8 $2.0 three March 31, 2020 Nil $0.2 three March 31, 2019 $0.1 $0.5

Note 5 - Warranty and Extended

Note 5 - Warranty and Extended Services Contract	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Product Warranty Disclosure [Text Block]	Note 5. The Company has a direct field service organization in North America (including Canada). Internationally, the Company provides direct service support in Australia, Belgium, France, Germany, Hong Kong, Japan, and Switzerland, as well as through third not third After the original warranty period, maintenance and support are offered on an extended service contract basis or on a time and materials basis. The Company provides for the estimated cost to repair or replace products under standard warranty at the time of sale. Costs incurred in connection with extended service contracts are recognized at the time when costs are incurred, except the one $3.2 December 31, 2018 one The following table provides the changes in the product standard warranty accrual for the three March 31, 2020 2019 Three Months Ended March 31, 20 20 201 9 Beginning Balance $ 4,401 $ 4,666 Add: Accruals for warranties issued during the period 860 1,444 Less: Settlements made during the period (1,863) (2,048) Ending Balance $ 3,398 $ 4,064 The $1.8 $2.0 three March 31, 2020 2019 $0.2 0.5 one

Note 6 - Deferred Revenue

Note 6 - Deferred Revenue	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Contract with Customer Liability [Text Block]	Note 6. The Company records deferred revenue when revenue is to be recognized subsequent to invoicing. For extended service contracts, the Company generally invoices customers at the beginning of the extended service contract term. The Company’s extended service contracts typically have one, two three 78% $12.9 March 31, 2020 12 The following table provides changes in the deferred revenue balance for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 Beginning Balance $ 14,222 $ 12,566 Add: Payments received 2,058 3,173 Less: Revenue (3,312) (2,649) Ending Balance $ 12,969 $ 13,090 Costs for extended service contracts were $2.2 $2.0 three March 31, 2020 2019,

Note 7 - Revenue

Note 7 - Revenue	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 7. Effective January 1, 2018, 606. 18% 15% three March 31, 2020 2019. The Company has certain system sale arrangements that contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct. The Company’s products and services are distinct if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer, and if the Company’s promise to transfer the products or service to the customer is separately identifiable from other promises in the sale arrangements. The Company’s system sale arrangements can include all or a combination of the following performance obligations: the system and software license (considered as one For the Company’s system sale arrangements that include an extended service contract, the period of service commences at the expiration of the Company’s standard warranty offered at the time of the system sale. The Company considers the extended service contracts terms in the arrangements that are legally enforceable to be performance obligations. Other than extended service contracts and marketing services, which are satisfied over time, the Company generally satisfies all performance obligations at a point in time. Systems, system accessories (hand pieces), service contracts, training, and time and materials services are also sold on a stand-alone basis, and these performance obligations are satisfied at a point in time. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price basis. Nature of Products and Services Systems Systems revenue is generated from the sale of systems and from the sale of upgrades to existing systems. A system consists of a console that incorporates a universal graphic user interface, a laser or other energy based module, control system software and high voltage electronics, as well as one Pearl Pearl Fractional The Company offers customers the ability to select the system that best fits their practice at the time of purchase and then to cost-effectively add applications to their system as their practice grows. This provides customers the flexibility to upgrade their systems whenever they choose and provides the Company with a source of additional Systems revenue. The system or upgrade and the right to use the embedded software represent a single performance obligation as the software license is integral to the functionality of the system or upgrade. The Company does not enlighten enlighten enlighten For systems sold directly to end-customers that are credit approved, revenue is recognized when the Company transfers control to the end-customer, which occurs when the product is shipped to the customer or when the customer receives the product, depending on the nature of the arrangement. When collectability is not The Company typically receives payment for its system consoles and other accessories within 30 Skincare products The Company sells third third third Consumables and other accessories The Company classifies its customers' purchases of replacement cycles for truSculpt iD and truSculpt flex, as well as replacement Titan and truSculpt 3D third Extended contract services The Company offers post-warranty services to its customers through extended service contracts that cover parts and labor for a term of one, two, or three Training Sales of systems to customers include training on the use of the system to be provided within 180 not Customer Marketing Support In North America, the Company offers marketing and consulting phone support to its customers across all system platforms. These customer marketing support services include a practice development model and marketing training, performed remotely with ongoing phone consultations for six six Significant Judgments The determination of whether two one may While the Company’s purchase agreements do not The Company determines standalone selling price ("SSP") for each performance obligation as follows: ● Systems: The SSPs for systems are based on directly observable sales in similar circumstances to similar customers. ● Training: SSP is based on observable price when sold on a standalone basis. ● Extended warranty/Service contracts: SSP is based on observable price when sold on a standalone basis (by customer type). ● Customer Marketing Support: SSP is estimated based on cost plus a margin. ● Set-up /Installation: SSP is based on observable price when sold on a standalone basis. The calibration and installation service of the enlighten enlighten Loyalty Program The Company launched a customer loyalty program during the third 2018 fifth March 31, 2020 December 31, 2019, $0.3 $0.2 Deferred Sales Commissions Incremental costs of obtaining a contract, which consist primarily of commissions and related payroll taxes, are capitalized and amortized on a straight-line basis over the expected period of benefit, except for costs that are recognized when product is sold. The Company uses the portfolio method to recognize the amortization expense related to these capitalized costs related to initial contracts and such expense is recognized over a period associated with the revenue of the related portfolio, which is generally two three Total capitalized costs as of the three twelve March 31, 2020 December 31, 2019, $4.1 $4.6 $0.7 $0.7 three March 31, 2020 March 31, 2019

Note 8 - Stockholders' Equity a

Note 8 - Stockholders' Equity and Stock-based Compensation Expense	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 8. The Company’s equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests. In June 2019, 2004 2019 “2019 700,000 9,701,192 2019 The Company’s Board of Directors granted its executive officers, senior management and certain employees 71,678 March 31, 2020. March 31, 2020 2020 The Company’s Board of Directors also granted its executive officers, senior management and certain employees 363,119 March 31, 2020. four 25% Under the 2004 262,560 three March 31, 2020, As of March 31, 2020, $18.3 2.67 may Activity under the 1998 2004 Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Exercise Price Balance, December 31, 201 9 761,705 295,699 $ 25.52 Stock awards granted (434,797) - - Options exercised - (22,291) 8.98 Options canceled 19,560 (19,560) 43.91 Stock awards canceled 343,911 - - Balance, March 31, 20 20 690,379 253,848 $ 25.55 Non-Employee Stock-Based Compensation The Company granted 9,134 March 31, 2020. March 31, 2020 2020 Stock-based Compensation Expense Stock-based compensation expense by department recognized during the three March 31, 2020 2019 Three Months Ended March 31, 20 20 201 9 Cost of revenue $ 290 $ 269 Sales and marketing 719 718 Research and development 321 263 General and administrative 650 57 Total stock-based compensation expense $ 1,980 $ 1,307

Note 9 - Net Loss Per Share

Note 9 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. In periods of net income, diluted shares outstanding include the dilutive effect of in-the-money equity awards (stock options, restricted stock units, performance stock units and employee stock purchase plan contributions), which is calculated based on the average share price for each fiscal period using the treasury stock method. Diluted earnings per share is the same as basic earnings per share for the periods in which the Company had a net loss because the inclusion of outstanding common stock equivalents would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): Three Months Ended March 31, 20 20 Three Months Ended March 31, 201 9 Numerator: Net loss $ (12,414) $ (8,220) Denominator: Weighted average shares of common stock outstanding used in computing net loss per share, basic 14,433 14,017 Dilutive effect of incremental shares and share equivalents - - Weighted average shares of common stock outstanding used in computing net loss per share, diluted 14,433 14,017 Net loss per share: Net loss per share, basic and diluted $ (0.86) $ (0.59) The following numbers of shares outstanding, prior to the application of the treasury stock method, were excluded from the computation of diluted net loss per common share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Three Months Ended March 31, 20 20 201 9 Options to purchase common stock 276 485 Restricted stock units 669 366 Performance stock units 216 21 Employee stock purchase plan shares 71 66 Total 1,232 938

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10. The Company calculates the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate for the full fiscal year to ordinary income or loss for the interim reporting period. When applicable, the year-to-date tax provision reflects adjustments from discrete tax items. For the three March 31, 2020, $78,000, $115,000 2019. three March 31, 2020 three March 31, 2020, not not March 27, 2020, not first not

Note 11 - Leases

Note 11 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Leases [Text Block]	Note 11. The Company is a party to certain operating and finance leases for vehicles, office space and storages facilities. The Company’s material operating leases consist of office space, as well as storage facilities, and finance leases are made up automobiles. The Company’s leases generally have remaining terms of 1 10 5 The Company determines if a contract contains a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The Company recognizes expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce the Company’s right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Supplemental balance sheet information related to leases was as follows (in thousands): Leases Classification March 31, 20 20 Assets Right-of-use assets Operating lease assets $ 7,143 Finance lease Property and equipment, net * 859 Total leased assets $ 8,002 * Finance lease assets included in Property and equipment, net. Liabilities Operating lease liabilities Operating lease liabilities, current Operating lease liabilities 2,204 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 5,149 Total Operating lease liabilities $ 7,353 Finance lease liabilities Finance lease liabilities, current Accrued liabilities * 541 Finance lease liabilities, non-current Operating lease liabilities 447 Total Finance lease liabilities $ 988 * Finance lease liabilities included in Accrued liabilities Lease costs as of March 31, 2020 Total amortization expense and interest expense for finance leases during the three March 31, 2020 $149 $19, three March 31, 2020 $728. Cash paid for amounts included in the measurement of lease liabilities during the three March 31, 2020 Operating cash flow from finance leases for the three $19. Financing cash flow from finance leases for the three $120. Operating cash flow from operating leases for the three $727. Facility leases Maturities of facility leases were as follows as of March 31, 2020 ( Year Ending March 31, Amount Remainder of 2020 $ 2,179 2021 2,650 2022 2,607 2023 326 2024 and thereafter 26 Total lease payments 7,788 Less: imputed interest 435 Present value of lease liabilities $ 7,353 Vehicle Leases As of March 31, 2020, Year Ending March 31, Amount Remainder of 2020 $ 408 2021 412 2022 253 2023 4 Total lease payments 1,077 Less: imputed interest 89 Present value of lease liabilities $ 988 Weighted-average remaining lease term and discount rate, as of March 31, 2020, Lease Term and Discount Rate March 31, 20 20 Weighted-average remaining lease term (years) Operating leases 2.8 Finance leases 2.5 Weighted-average discount rate Operating leases 4.4 % Finance leases 5.6 %

Note 12 - Contingencies

Note 12 - Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 12. The Company is named from time to time as a party to other legal proceedings, product liability, commercial disputes, employee disputes, and contractual lawsuits in the normal course of business. A liability and related charge are recorded to earnings in the Company’s consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no not In November 2019, November 7, 2019, not not As of March 31, 2020 December 31, 2019, no not

Note 13 - Debt

Note 13 - Debt	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 13. On May 30, 2018, $25 May 30, 2021. On or about November 2, 2018, $15 $10 On or about March 11, 2019, $15 no may twelve not $10 not 2.5 1.0. On or about March 19, 2020, $15 second no As of March 31, 2020, not

Note 14 - Segment Reporting

Note 14 - Segment Reporting	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 14. Segment reporting is based on the “management approach,” following the method that management organizes the company’s reportable segments for which separate financial information is made available to, and evaluated regularly by, the chief operating decision maker in allocating resources and in assessing performance. The Company’s chief operating decision maker ("CODM") is its Chief Executive Officer ("CEO"), who makes decisions on allocating resources and in assessing performance. The CEO reviews the Company's consolidated results as one one one The following table presents a summary of revenue by geography for the three March 31, 2020 2019 Three Months Ended March 31, 20 20 201 9 Revenue mix by geography: United States $ 13,784 $ 20,400 Japan 7,162 5,294 Asia, excluding Japan 3,229 3,095 Europe 2,816 2,736 Rest of the world 5,248 4,501 Total consolidated revenue $ 32,239 $ 36,026 Revenue mix by product category: Products $ 20,958 $ 27,209 Consumables 2,533 1,945 Skincare 2,900 1,608 Total product revenue $ 26,391 $ 30,762 Service 5,848 5,264 Total consolidated revenue $ 32,239 $ 36,026

Note 15 - Subsequent Events

Note 15 - Subsequent Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 15. The Company has determined that there are no On April 6, 2020 April 27, 2020, 2019 42% In addition, in order to further conserve cash, settlement terms of the 2019 10% 100% 141,610 April 2020, On April 21, 2020, 2,742,750 $0.001 $10.50 April 16, 2020 ( The shares include the full exercise of the underwriter’s option to purchase an additional 357,750 3 No. 333 237552 April 14, 2020, April 14, 2020 April 16, 2020. The Company received net proceeds from the offering of approximately $26.7 may not On April 22, 2020, $7.1 The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. Subsequently released guidance instructs all applicants and recipients to take into account their current business activity and the Company's ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not April 28, 2020, $2.0 may The loan, which is in the form of a promissory note, dated April 21, 2020, April 21, 2022 1.00% six no may No not

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) provides energy-based aesthetic systems for practitioners worldwide. The Company designs, develops, manufactures, distributes and markets energy-based product platforms for use by physicians and other qualified practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: excel, enlighten, Juliet, Secret RF, truSculpt xeo truSculpt iD truSculpt flex Juliet Secret RF third Titan, truSculpt 3D, truSculpt flex The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company markets, sells and services the Company’s products through direct sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland and the United Kingdom. Sales and Services outside of these direct markets are made through a worldwide distributor network in over 40
Risks and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not On January 30, 2020, 19 In March 2020, 19 19 19 19 third 19 120 180 Beginning in the second first 2020, 19, not In cases where its customers are working, they are performing fewer procedures. When they are performing procedures, customers are mostly focused on medically necessary procedures that should not may may second 2020, 2020, may In response to the COVID- 19 25% 25% 42% 2019 As a result of the events and impact surrounding the COVID- 19 no March 31, 2020. COVID–19
Unaudited Interim Financial Information [Policy Text Block]	Unaudited Interim Financial Information In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements included in this report reflect all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of its consolidated statements of financial position as of March 31, 2020 2019, three March 31, 2020, 2019. December 31, 2019 not not 10 December 31, 2019 March 16, 2020.
Basis of Accounting, Policy [Policy Text Block]	Accounting Policies These unaudited condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not 10 December 31, 2019 March 16, 2020. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the Notes to condensed consolidated financial statements refer to the Company’s continuing operations. Note 1
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, and sales allowances, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, incremental borrowing rates related to the Company’s leases, assumptions regarding variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, fair value of investments, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In June 2016, No. 2016 13, 326 2016 13 December 15, 2019, 2020, 2016 13 January 1, 2020 not The Company identified trade receivables and available-for-sale debt securities as impacted by the new guidance. However, the Company determined that the historical losses related to these available-for-sale debt securities are not The Company establishes an allowance for credit losses on trade receivables based on the credit quality of clients, current economic conditions, the age of the accounts receivable balances, historical loss information, and current conditions and forecasted information, and write-off amounts against the allowance when they are deemed uncollectible. At March 31, 2020 three March 31, 2020, 19 The Company’s allowance for credit losses was $937,000 $1,354,000 March 31, 2020 December 31, 2019. March 31, 2020, $590,000 $1,007,000 In August 2018, No. 2018 13, 820 3 1 2 3 2020, not Recently Issued Accounting Pronouncements Not In December 2019, No. 2019 12 740 2021, not

Note 2 - Cash, Cash Equivalen_2

Note 2 - Cash, Cash Equivalents and Marketable Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Unrealized Gain (Loss) on Investments [Table Text Block]	March 31, 20 20 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Cash and cash equivalents $ 14,774 $ - $ - $ 14,774 Marketable investments: U.S. government notes 804 1 - 805 Commercial paper 3,941 1 (1 ) 3,941 Total marketable investments 4,745 2 (1 ) 4,746 Total cash, cash equivalents and marketable investments $ 19,519 $ 2 $ (1 ) $ 19,520 December 31, 2019 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Market Value Cash and cash equivalents $ 26,316 $ - $ - $ 26,316 Marketable investments U.S. government notes 4,114 - - 4,114 Commercial paper 3,491 - - 3,491 Total marketable securities 7,605 - - 7,605 Total cash, cash equivalents and marketable securities $ 33,921 $ - $ - $ 33,921
Investments Classified by Contractual Maturity Date [Table Text Block]	Amount Due in less than one year $ 4,746 Due in 1 to 3 years - Total marketable investments $ 4,746

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	March 31, 20 20 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 9,224 $ - $ - $ 9,224 Marketable investments: Available-for-sale securities 805 3,941 - 4,746 Total assets at fair value $ 10,029 $ 3,941 $ - $ 13,970 December 31, 2019 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds $ 6,311 $ - $ - $ 6,311 Short term marketable investments: Available-for-sale securities 4,114 3,491 - 7,605 Total assets at fair value $ 10,425 $ 3,491 $ - $ 13,916

Note 4 - Balance Sheet Detail (

Note 4 - Balance Sheet Detail (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 20 20 December 31, 201 9 Raw materials $ 19,092 $ 17,935 Work in process 3,161 2,016 Finished goods 14,688 13,970 Total $ 36,941 $ 33,921
Schedule of Accrued Liabilities [Table Text Block]	March 31, 20 20 December 31, 201 9 Accrued payroll and related expenses $ 11,842 $ 14,341 Sales and marketing accruals 1,581 2,527 Warranty liability 3,398 4,401 Sales tax 1,443 3,922 Other 5,399 5,116 Total $ 23,663 $ 30,307

Note 5 - Warranty and Extende_2

Note 5 - Warranty and Extended Services Contract (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Three Months Ended March 31, 20 20 201 9 Beginning Balance $ 4,401 $ 4,666 Add: Accruals for warranties issued during the period 860 1,444 Less: Settlements made during the period (1,863) (2,048) Ending Balance $ 3,398 $ 4,064

Note 6 - Deferred Revenue (Tabl

Note 6 - Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended March 31, 2020 2019 Beginning Balance $ 14,222 $ 12,566 Add: Payments received 2,058 3,173 Less: Revenue (3,312) (2,649) Ending Balance $ 12,969 $ 13,090

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity and Stock-based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Exercise Price Balance, December 31, 201 9 761,705 295,699 $ 25.52 Stock awards granted (434,797) - - Options exercised - (22,291) 8.98 Options canceled 19,560 (19,560) 43.91 Stock awards canceled 343,911 - - Balance, March 31, 20 20 690,379 253,848 $ 25.55
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 20 20 201 9 Cost of revenue $ 290 $ 269 Sales and marketing 719 718 Research and development 321 263 General and administrative 650 57 Total stock-based compensation expense $ 1,980 $ 1,307

Note 9 - Net Loss Per Share (Ta

Note 9 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 20 20 Three Months Ended March 31, 201 9 Numerator: Net loss $ (12,414) $ (8,220) Denominator: Weighted average shares of common stock outstanding used in computing net loss per share, basic 14,433 14,017 Dilutive effect of incremental shares and share equivalents - - Weighted average shares of common stock outstanding used in computing net loss per share, diluted 14,433 14,017 Net loss per share: Net loss per share, basic and diluted $ (0.86) $ (0.59)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 20 20 201 9 Options to purchase common stock 276 485 Restricted stock units 669 366 Performance stock units 216 21 Employee stock purchase plan shares 71 66 Total 1,232 938

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Leases, Financial Statement Information [Table Text Block]	Leases Classification March 31, 20 20 Assets Right-of-use assets Operating lease assets $ 7,143 Finance lease Property and equipment, net * 859 Total leased assets $ 8,002 Liabilities Operating lease liabilities Operating lease liabilities, current Operating lease liabilities 2,204 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 5,149 Total Operating lease liabilities $ 7,353 Finance lease liabilities Finance lease liabilities, current Accrued liabilities * 541 Finance lease liabilities, non-current Operating lease liabilities 447 Total Finance lease liabilities $ 988
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending March 31, Amount Remainder of 2020 $ 2,179 2021 2,650 2022 2,607 2023 326 2024 and thereafter 26 Total lease payments 7,788 Less: imputed interest 435 Present value of lease liabilities $ 7,353
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	Year Ending March 31, Amount Remainder of 2020 $ 408 2021 412 2022 253 2023 4 Total lease payments 1,077 Less: imputed interest 89 Present value of lease liabilities $ 988
Lease, Cost [Table Text Block]	Lease Term and Discount Rate March 31, 20 20 Weighted-average remaining lease term (years) Operating leases 2.8 Finance leases 2.5 Weighted-average discount rate Operating leases 4.4 % Finance leases 5.6 %

Note 14 - Segment Reporting (Ta

Note 14 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three Months Ended March 31, 20 20 201 9 Revenue mix by geography: United States $ 13,784 $ 20,400 Japan 7,162 5,294 Asia, excluding Japan 3,229 3,095 Europe 2,816 2,736 Rest of the world 5,248 4,501 Total consolidated revenue $ 32,239 $ 36,026 Revenue mix by product category: Products $ 20,958 $ 27,209 Consumables 2,533 1,945 Skincare 2,900 1,608 Total product revenue $ 26,391 $ 30,762 Service 5,848 5,264 Total consolidated revenue $ 32,239 $ 36,026

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Reduction in Board of Directors Fees in Response to COVID19 Outbreak, Percentage	25.00%
Reduction in Salaries of Chief Executive Officer, President, Chief Operating Officer and Some Managers in Response to COVID 19 Outbreak, Percentage	25.00%
Reduction in Salaries of Employees and Furloughs in Response to COVID 19 Outbreak, Percentage of Workforce	42.00%
Accounts Receivable, Allowance for Credit Loss, Current	$ 937,000		$ 1,354,000
Accounts Receivable, Credit Loss Expense (Reversal)	590,000	$ 98,000
Accounts Receivable, Allowance for Credit Loss, Writeoff	$ 1,007,000

Note 2 - Cash, Cash Equivalen_3

Note 2 - Cash, Cash Equivalents and Marketable Investments (Details Textual) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale, Net Accumulated Gross Unrealized Gain (Loss), before Tax	$ 1,000	$ 0
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	$ 0

Note 2 - Cash, Cash Equivalen_4

Note 2 - Cash, Cash Equivalents and Marketable Investments - Unrealized Gains and Losses Related to Marketable Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Cash and cash equivalents and marketable investments, amortized cost	$ 19,519	$ 33,921
Cash and cash equivalents and marketable investments, Fair Market Value	19,520	33,921
Cash and cash equivalents and marketable investments, amortized cost, Gross Unrealized Gains	2
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(1)
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(2)
US Treasury and Government [Member]
Cash and cash equivalents and marketable investments, amortized cost	804	4,114
Cash and cash equivalents and marketable investments, Fair Market Value	805	4,114
Cash and cash equivalents and marketable investments, amortized cost, Gross Unrealized Gains	1
Cash and cash equivalents and marketable investments, Gross Unrealized Losses
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(1)
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Cash and cash equivalents and marketable investments, amortized cost	3,941	3,491
Cash and cash equivalents and marketable investments, Fair Market Value	3,941	3,491
Cash and cash equivalents and marketable investments, amortized cost, Gross Unrealized Gains	1
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(1)
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(1)
Marketable Investments [Member]
Cash and cash equivalents and marketable investments, amortized cost	4,745	7,605
Cash and cash equivalents and marketable investments, Fair Market Value	4,746	7,605
Cash and cash equivalents and marketable investments, amortized cost, Gross Unrealized Gains	2
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(1)
Cash and cash equivalents and marketable investments, Gross Unrealized Losses	(2)
Cash and Cash Equivalents [Member]
Cash and cash equivalents and marketable investments, amortized cost	14,774	26,316
Cash and cash equivalents and marketable investments, Fair Market Value	$ 14,774	$ 26,316

Note 2 - Cash, Cash Equivalen_5

Note 2 - Cash, Cash Equivalents and Marketable Investments - Maturities of Available-for-sale Securities (Details) $ in Thousands	Mar. 31, 2020USD ($)
Due in less than one year	$ 4,746
Due in 1 to 3 years
Total marketable investments	$ 4,746

Note 3 - Fair Value of Financ_3

Note 3 - Fair Value of Financial Instruments (Details Textual)	3 Months Ended
	Mar. 31, 2020
Fair Value, Inputs, Level 2 [Member]
Average Remaining Maturity of Investment (Year)	36 days

Note 3 - Fair Value of Financ_4

Note 3 - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Cash equivalents:
Available-for-sale securities	$ 4,746	$ 7,605
Total assets at fair value	13,970	13,916
Marketable investments:
Available-for-sale securities	4,746	7,605
Total assets at fair value	13,970	13,916
Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Available-for-sale securities	805	4,114
Total assets at fair value	10,029	10,425
Marketable investments:
Available-for-sale securities	805	4,114
Total assets at fair value	10,029	10,425
Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Available-for-sale securities	3,941	3,491
Total assets at fair value	3,941	3,491
Marketable investments:
Available-for-sale securities	3,941	3,491
Total assets at fair value	3,941	3,491
Money Market Funds [Member]
Cash equivalents:
Cash Equivalents	9,224	6,311
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Cash Equivalents	$ 9,224	$ 6,311

Note 4 - Balance Sheet Detail_2

Note 4 - Balance Sheet Detail (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Standard Product Warranty Accrual, Ending Balance	$ 3,398	$ 4,064	$ 4,666	$ 4,401
Standard Product Warranty Accrual, Decrease for Payments	1,863	2,048
Product Remediation Liability [Member]
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued, Total			$ 5,000
Standard Product Warranty Accrual, Ending Balance	500			500
Extended Product Warranty Accrual, Ending Balance	1,800			$ 2,000
Standard Product Warranty Accrual, Decrease for Payments	0	100
Standard Product Warranty Accrual, Decrease for Payments	$ 200	$ 500

Note 4 - Balance Sheet Detail -

Note 4 - Balance Sheet Detail - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Raw materials	$ 19,092	$ 17,935
Work in process	3,161	2,016
Finished goods	14,688	13,970
Total	$ 36,941	$ 33,921

Note 4 - Balance Sheet Detail_3

Note 4 - Balance Sheet Detail - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued payroll and related expenses	$ 11,842	$ 14,341
Sales and marketing accruals	1,581	2,527
Warranty liability	3,398	4,401
Sales tax	1,443	3,922
Other	5,399	5,116
Total	$ 23,663	$ 30,307

Note 5 - Warranty and Extende_3

Note 5 - Warranty and Extended Services Contract (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Extended Product Warranty Accrual, Current	$ 1,765		$ 1,999	$ 3,200
Standard Product Warranty Accrual, Decrease for Payments	1,863	$ 2,048
Product Remediation Liability [Member]
Standard Product Warranty Accrual, Decrease for Payments	0	100
Standard Product Warranty Accrual, Decrease for Payments	$ 200	$ 500

Note 5 - Warranty and Extende_4

Note 5 - Warranty and Extended Services Contract - Summary of Warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 4,401	$ 4,666
Add: Accruals for warranties issued during the period	860	1,444
Less: Settlements made during the period	(1,863)	(2,048)
Balance	$ 3,398	$ 4,064

Note 6 - Deferred Revenue (Deta

Note 6 - Deferred Revenue (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue, Remaining Performance Obligation, Percentage	78.00%
Revenue, Remaining Performance Obligation, Amount	$ 12.9
Deferred Revenue Costs Incurred	$ 2.2	$ 2

Note 6 - Deferred Revenue - Sum

Note 6 - Deferred Revenue - Summary of Deferred Service Contract Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 14,222	$ 12,566
Add: Payments received	2,058	3,173
Less: Revenue	(3,312)	(2,649)
Balance	$ 12,969	$ 13,090

Note 7 - Revenue (Details Textu

Note 7 - Revenue (Details Textual) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Selling and Marketing Expense [Member]
Capitalized Contract Cost, Amortization	$ 0.7		$ 0.7
Other Assets [Member]
Capitalized Contract Cost, Net, Total	4.1		4.6
Loyalty [Member]
Contract with Customer, Liability, Total	$ 0.3		$ 0.2
Transferred over Time [Member]
Revenue from Contract with Customer, Including Assessed Tax, Percent of Total Revenues	18.00%	15.00%

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual) - USD ($) $ in Millions	Jun. 14, 2019	Mar. 31, 2020
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 18.3
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 244 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		71,678
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		363,119
Restricted Stock Units (RSUs) [Member] | Non-employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		9,134
Two Thousand Nineteen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	700,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	9,701,192
Two Thousand Nineteen Equity Incentive Plan [Member] | Performance Shares [Member] | Tranche 2020 [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Two Thousand Nineteen Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
2004 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Ownership Plan (in shares)		262,560

Note 8 - Stockholders' Equity_4

Note 8 - Stockholders' Equity and Stock-based Compensation Expense - Activity Under the 2004 Equity Incentive Plan (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Balance, shares available for grant (in shares)	761,705
Balance, stock options outstanding (in shares)	295,699
Balance, weighted-average exercise price (in dollars per share) | $ / shares	$ 25.52
Stock awards granted, shares available for grant (in shares)	(434,797)
Options exercised, stock options outstanding (in shares)	(22,291)
Options exercised, weighted-average exercise price (in dollars per share) | $ / shares	$ 8.98
Options canceled, shares available for grant (in shares)	19,560
Options canceled, stock options outstanding (in shares)	(19,560)
Options canceled, weighted-average exercise price (in dollars per share) | $ / shares	$ 43.91
Stock awards canceled (in shares)	343,911
Balance, shares available for grant (in shares)	690,379
Balance, stock options outstanding (in shares)	253,848
Balance, weighted-average exercise price (in dollars per share) | $ / shares	$ 25.55

Note 8 - Stockholders' Equity_5

Note 8 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense by Department (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Allocated Share Based Compensation Expense	$ 1,980	$ 1,307
Cost of Sales [Member]
Allocated Share Based Compensation Expense	290	269
Selling and Marketing Expense [Member]
Allocated Share Based Compensation Expense	719	718
Research and Development Expense [Member]
Allocated Share Based Compensation Expense	321	263
General and Administrative Expense [Member]
Allocated Share Based Compensation Expense	$ 650	$ 57

Note 9 - Net Loss Per Share - N

Note 9 - Net Loss Per Share - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss	$ (12,414)	$ (8,220)
Weighted average shares of common stock outstanding used in computing net loss per share, basic (in shares)	14,433	14,017
Dilutive effect of incremental shares and share equivalents (in shares)
Weighted average shares of common stock outstanding used in computing net loss per share, diluted (in shares)	14,433	14,017
Net loss per share, basic and diluted (in dollars per share)	$ (0.86)	$ (0.59)

Note 9 - Net Loss Per Share - A

Note 9 - Net Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities (in shares)	1,232	938
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	276	485
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	669	366
Performance Shares [Member]
Antidilutive Securities (in shares)	216	21
ESPP [Member]
Antidilutive Securities (in shares)	71	66

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Expense (Benefit), Total	$ 78,000	$ 115,000

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Finance Lease, Right-of-Use Asset, Amortization	$ 149
Finance Lease, Interest Expense	19
Operating Lease, Expense	728
Finance Lease, Interest Payment on Liability	19
Finance Lease, Principal Payments	183	$ 131
Operating Lease, Payments	$ 727
Minimum [Member]
Lessee, Leases, Remaining Term (Year)	1 year
Maximum [Member]
Lessee, Leases, Remaining Term (Year)	10 years
Lessee, Lease, Renewal Term (Year)	5 years

Note 11 - Leases - Financial St

Note 11 - Leases - Financial Statement Information (Details) - USD ($) $ in Thousands		Mar. 31, 2020	Dec. 31, 2019
Right-of-use assets		$ 7,143	$ 7,702
Total leased assets		8,002
Operating lease liabilities, current		2,204	2,800
Operating lease liabilities, non-current		5,149	$ 5,112
Present value of lease liabilities		7,353
Finance lease liabilities, current	[1]	541
Finance lease liabilities, non-current		447
Present value of lease liabilities		988
Operating Lease Assets [Member]
Right-of-use assets		7,143
Operating Lease Liabilities [Member]
Operating lease liabilities, current		2,204
Property and Equipment, Net [Member]
Finance lease	[1]	859
Operating Lease Liabilities, Net of Current Portion [Member]
Operating lease liabilities, non-current		$ 5,149
[1]	Finance lease assets included in Property and equipment, net.

Note 11 - Leases - Maturities o

Note 11 - Leases - Maturities of Operating Lease Liabilities (Details) $ in Thousands	Mar. 31, 2020USD ($)
Present value of lease liabilities	$ 7,353
Facility Operating Leases [Member]
Remainder	2,179
2021	2,650
2022	2,607
2023	326
2024 and thereafter	26
Total lease payments	7,788
Less: imputed interest	435
Present value of lease liabilities	$ 7,353

Note 11 - Leases - Maturities_2

Note 11 - Leases - Maturities of Finance Leases Liabilities (Details) $ in Thousands	Mar. 31, 2020USD ($)
Present value of lease liabilities	$ 988
Vehicle Finance Leases [Member]
Remainder	408
2021	412
2022	253
2023	4
Total lease payments	1,077
Less: imputed interest	89
Present value of lease liabilities	$ 988

Note 11 - Leases - Lease Inform

Note 11 - Leases - Lease Information (Details)	Mar. 31, 2020
Operating leases (Year)	2 years 292 days
Finance leases (Year)	2 years 182 days
Operating leases	4.40%
Finance leases	5.60%

Note 12 - Contingencies (Detail

Note 12 - Contingencies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Estimated Litigation Liability	$ 0	$ 0

Note 13 - Debt (Details Textual

Note 13 - Debt (Details Textual) $ in Thousands	Mar. 11, 2019USD ($)	Mar. 31, 2020USD ($)	Nov. 02, 2018USD ($)	May 30, 2018USD ($)
Revolving Line of Credit [Member] | Wells Fargo [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 25,000
Revised Revolving Line of Credit [Member] | Wells Fargo [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 15,000
Line of Credit Facility, Additional Requestable Maximum Borrowing Capacity			$ 10,000
Debt Instrument, Debt Covenant, Minimum Unrestricted Cash Balance	$ 15,000
Revolving Credit Facility [Member]
Debt Instrument, Minimum Adjusted EBITDA	$ 10,000
Leverage Ratio, Maximum	2.5
Debt Instrument, Covenant, Minimum Cash, Cash Equivalents, and Marketable Securities Balance		$ 15,000
Long-term Line of Credit, Total		$ 0

Note 14 - Segment Reporting (De

Note 14 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2020
Number of Operating Segments	1

Note 14 - Segment Reporting (_2

Note 14 - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 32,239	$ 36,026
Products Excluding Consumables and Skincare [Member]
Revenue	20,958	27,209
Hand Piece Refills [Member]
Revenue	2,533	1,945
Skincare [Member]
Revenue	2,900	1,608
Product [Member]
Revenue	26,391	30,762
Service [Member]
Revenue	5,848	5,264
UNITED STATES
Revenue	13,784	20,400
JAPAN
Revenue	7,162	5,294
Asia, Excluding Japan [Member]
Revenue	3,229	3,095
Europe [Member]
Revenue	2,816	2,736
Rest of World [Member]
Revenue	$ 5,248	$ 4,501

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Apr. 22, 2020	Apr. 21, 2020	Apr. 01, 2020	Apr. 27, 2020	Mar. 31, 2020	Dec. 31, 2019
Common Stock, Par or Stated Value Per Share (in dollars per share)					$ 0.001	$ 0.001
Subsequent Event [Member]
Percentage of Workforce, Reduction				42.00%
Percentage of Cash Bonuses Onwed Settled in Cash				10.00%
Percentage of Cash Bonuses Owned Paid in RSUs				100.00%
Number of RSUs Issued for Settlement of Cash Bonuses (in shares)			141,610
Proceeds from Paycheck Protection Program Under CARES Act	$ 7.1
Subsequent Event [Member] | Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		2,742,750
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001
Shares Issued, Price Per Share (in dollars per share)		$ 10.50
Proceeds from Issuance of Common Stock		$ 26.7
Subsequent Event [Member] | Underwritten Public Offering [Member] | Underwriter [Member]
Stock Issued During Period, Shares, New Issues (in shares)		357,750